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Inaugural Target Discovery World
Congress 2009
San Francisco, CA, USA, 4–5 August 2009
Target Discovery World Congress 2009 is the first of its kind in a series of trend-setting conferences conceived
and organized by Select Biosciences. This was a multi-track event with a combined exhibition covering current
potential drug targets, the platforms used to screen for hits and hit-to-lead methods. This conference included all
the major drug-target classes: ion channels, protein kinases, G-protein-coupled receptors, nuclear receptors and
ubiquitin pathways, as well as a special session devoted to screening platforms in academia. Each of the sessions
started with a noteworthy keynote presentation by a world-class expert. There were a total of 44 high-quality
podium presentations and 16 poster presentations.

The pharmaceutical industry is at a critical
juncture now, with R&D costs escalating in
leaps and bounds, and productivity, as indicated by investigational new drug filings, lagging far behind. This disconnect seems to be
attributed to the difficulty in conquering the
so-called ‘valley of death’, the Phase II clinical trials, where safety and efficacy of drug
candidates are critically assessed. There is
an almost 80% failure rate during Phase II
clinical trials and almost half of this can be
attributed to target-related failures. It is generally perceived that the pharmaceutical industry greatly underestimates the significance of
patho/toxicobiology, and not well enough to
pick the right therapeutic targets and, hence,
the right drug candidates. It is academia, not
the pharmaceutical industry, that is engaged
in elucidating the mechanistic aspects of disease biology. In this context, the timing of
the Target Discovery World Congress could
not be overemphasized. The number of US
FDA-approved drugs target less than 0.05%
of genes, that is, 106 out of 25,500 in the
human genome, and the rate of discovery for
drugs that act on new therapeutic targets has
been flat or on a downward trend for the last
quarter of a century. Drug repurposing (finding new uses for old drugs) is the new mantra
for many pharmaceutical companies. This new
endeavor infers that, for many targets, there is
more than one drug and that many drugs are
promiscuous, targeting more than one protein.
With more than US$50 billion being spent on
research each year, it is quite alarming to know
that the pharmaceutical industry cannot confidently affirm the selectivity and specificity of
the drugs it markets.

It is time to critically interrogate the drug
gable human genome to expand the target
universe and facilitate the discovery of new,
novel and safer drugs with greater selectivity
and specificity. The conference keynote presentation by Rathnam Chaguturu (University
of Kansas, KS, USA) stressed the need for both
pharma and academia to engage in a partnership
where the core missions of each institution are
recognized, respected and accommodated, to
conquer the so-called ‘valley of death’. Instead
of relying on small molecule-centric, forwardgenetic chemical approaches based on protein
targets, he stressed the need for a paradigm
shift where the focus is laid on genetic switches
underlying the disease causing genome. PTC
Therapeutics’ ataluren targeting untranslated regulatory sequences of RNA is a prime
example of such a groundbreaking endeavor.
Track 1: screening methods
& techniques
The session brought together the Directors of
several academic screening centers as well as
faculty involved in ground-breaking research
related to screening technologies. The session
started with a keynote presentation by Rathnam
Chaguturu. He discussed the drug-discovery
and development initiatives at the University
of Kansas fostering a matrix-team approach, a
pharmaceutical industry-based best practice, in
bridging the gap between in vitro drug target
screening and in vivo validation, so as to make
drug discovery in academia a reality.
Thomas Chung (Burnham Institute for
Medical Research, CA, USA) provided an overview of Burnham’s experiences in the network,
from the pilot Molecular Libraries Screening
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Centers Network to the production phase of
the Molecular Libraries Probe Production
Centers Network phase in overcoming technical and organizational challenges to forming a
worthwhile national resource for the academic,
not-for-profit and commercial research organizations. With almost 1300 bioassays and
over 35 million datapoints deposited into the
PubChem database, the MLSCN/MLPCN
programs of the NIH have identified less than
40 probes with submicromolar potency, thus
illustrating the enormous difficulty in identifying probes against novel therapeutic targets.
One could also attribute this to inefficiency in
coordinating therapeutic biology with medicinal chemistry, a rare combination of skills in
the biomedical science community that is more
biology-oriented.
With governmental agencies such as the
NIH in the USA and the Medical Research
Council in the UK funding cutting-edge
research in target discovery, there is an evergrowing need for new signal detection technologies and platforms to facilitate the associated
probe discovery and development efforts. Alan
Waggoner (Carnegie Mellon University, PA,
USA) discussed his team’s efforts in developing a tool kit of fluorescent probes (biosensors)
for quantifying the protein-regulation pathways
of living cells at high resolution. The biosensordevelopment program blends genetics, protein
structure, nucleic acid structure and fluorescent
dye chemistry. His biosensor platform consists
of single-chain antibodies that bind fluorogen
dyes with high affinity and large fluorescence
increases, and holds huge promise for exploring
biomolecular interactions. Larry Sklar (Director
of the University of New Mexico Center for
Molecular Discovery for the NIH Roadmap
Molecular Libraries Initiative) described the
unique capabilities of flow cytometry towards
homogeneous detection of molecular assembly,
analysis of binding affinity and subsecond resolution of binding kinetics, often with femtomole
sensitivity. This renewed appreciation offers
exceptional opportunities for flow cytometry
relating to receptor assembly and pharmacology, as well as a range of screening applications.
Brian Cunningham (University of Illinois, IL,
USA) presented novel label-free high-throughput screening of small molecule–protein interactions, cytotoxicity and G-protein-coupled
receptor (GPCR) agonism/antagonism using
photonic crystal optical biosensors incorporated
into standard format microplates.
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Target validation is becoming much more
important and relevant in overcoming the ‘valley
of death’ and high-content assay technology has
found its niche in addressing this growing concern. High-content screening (HCS) technology makes use of spatially or temporally resolved
imaging of cells using fluorescent tags to measure intracellular changes at the organelle level.
Presentations by Hakim Djaballah (Memorial
Sloan Kettering Cancer Center, NY, USA),
Susan Heynen-Genel (Burnham Institute,
CA, USA) and Joseph Trask (Duke University
Medical Center, NC, USA) affirmed that the
HCS platform is now a mainstream screening
technology platform. BioFocus™ now has an
HCS platform for identifying inhibitors of cell
migration in cancer metastasis using adenoviral
knockdown in a wound-healing assay. HCS data
analysis is still a herculean task, as exemplified
by Vebjørn Ljosa’s (Broad Institute of Harvard
and MIT, MA, USA) talk, which describing the
capabilities of CellProfiler™, an open-source
software for measuring cells and organisms in
large-scale microscopy image sets.
Track 2: targeting protein kinases,
nuclear receptors & ubiquitin
proteosome system
Kinases
Keynote presentation by Andrei Gartel
(University of Illinois, IL, USA) affirmed
the paradigm shift advocated by Rathnam
Chaguturu by showing the repression of the
transcriptional activity of FoxM1, an attractive
therapeutic target in cancer, as well as FoxM1
expression by thiazole antibiotics, siomycin A
and thiostrepton. This new mode of regulation
of FoxM1 is another successful example of targeting the genetic switch rather than modulating
the activity of the expressed protein in achieving
disease prevention.
With Gleevec® sales exceeding US$3 billion,
the relatively young field of targeting protein
kinases for drug discovery has gained unprecedented momentum. The pharmaceutical industry is now heavily focused on this class of targets
for the treatment of a number of diseases, especially cancer and CNS disorders. The first wave
of Aurora kinase inhibitors are entering clinical
trials (Spiros Linardopoulos, Institute for Cancer
Research, London, UK), and lipid kinases are a
new class of drug targets being pursued (Jen Pan,
Broad Institute, CA, USA). With the ubiquitous presence of kinases in cancer cells, targeting the noncatalytic/allosteric domains seems
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to be key in achieving kinase selectivity and
specificity, thereby minimizing clinical uncertainty (Jen Pan, Broad Institute, MA, USA, and
Ariel Fernandez, Rice University, TX, USA).
Wendell Wierenga (Ambit Biosciences, CA,
USA) discussed the utility of KinomeScan™
in generating uniquely selective kinase inhibitors for various indications in oncology and
autoimmune diseases.
Nuclear

receptors & ubiquitin pathway
Nuclear receptors are ligand-activated transcription factors that include the receptors for steroid
and thyroid hormones, retinoic acid, oxysterols
and bile acids. A total of 48 members of this
superfamily of receptors exist in humans, and
a significant number of these have no identified ligands. The vast majority of nuclear receptors that have identified ligands are targets for
marketed drugs that treat diseases including
cancer, inflammation and metabolic syndrome.
Thus, the remaining orphan members of the
superfamily may be a rich source of targets for
the development of novel therapeutics. A keynote presentation by Thomas Burris (Scripps
Research Institute, CA, USA) highlighted
these aspects of nuclear receptor biology and his
team’s success in identifying both physiological
and synthetic ligands for several orphan nuclear
receptors. Fredika Robertson (MD Anderson
Cancer Center, TX, USA) has made the case
for targeting histone deacetylases to reprogram
breast cancer stem cells. Histone deacetylase
inhibitors target the self-renewal and pleuripotency of breast cancer stem cells, while simultaneously reprogramming expression of such genes
as estrogen receptors, resulting in the return of
responsiveness to anti-estrogen therapy.
With the therapeutic validation of the ubiquitin–proteasome system, as evidenced by the
marketing approval of bortezomib (Velcade®/
PS-341) for the treatment of multiple myeloma,
Suresh Kumar (Progenera Corporation) discussed the discovery and development of
novel USP7 inhibitors that selectively inhibit
the growth of human tumor cells but not
normal cells.
Track 3: targeting G-protein-coupled
receptors & cell signaling systems
Keynote presentation by Jeffrey Conn
(Vanderbilt University, TE, USA) clearly articulated an exciting new approach to the discovery of highly selective, allosteric activators
and antagonists of metabotropic glutamate and
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muscarinic acetylcholine receptors, which have
robust activity in multiple animal models that
predict efficacy in treatment of CNS disorders.
Milt Teitler (Albany Medical College, NY, USA)
presented evidence for functional homodimers
to explain rapid
�����������������������������������
and potent drug-induced inactivation and reactivation of serotonin receptors,
using risperidone, 9-OH-risperidone and other
drugs as case studies.
At the technology front, Bing Xie (CisBio
Ltd, MA, USA) talked about new homogenous
time-resolved flourescence (HTRF) solutions
for cell-surface receptors, by monitoring cAMP
(adenylate cyclase) and IP (phospholipase C).
The combination of Lumi4®-Tb cryptate chemistry and SNAP-Tag™-labeling technology
broadens HTRF applications, such as providing
a nonradioactive alternative in ligand-binding
assays and comprehensive investigation in receptor mechanistics (internalization and dimerization). Alexei Yeliseev (NIH, USA) discussed
the use of NMR spectroscopy to elucidate the
structure of human cannabinoid receptor CB2,
one of the most sought after pharmaceutical
targets. Hans Brauner-Osbourne (University
of Copenhagen, Denmark) reported the cloning and analysis of expression of a novel human
family C G-protein-coupled receptor, termed
GPRC6A. Homology modeling of the GPRC6A
amino terminal domain based on the crystal structure of the metabotropic glutamate
receptor subtype 1 predicted interaction with
a-amino acids, and was employed to rationally
select potential ligands.
A number of therapeutic targets have been
developed to address the problem of uncontrolled platelet activation leading to vessel
occlusion and subsequent stroke. These targets
have focused on direct inhibition of G-proteincoupled receptor and integrin receptors as well
as the inhibition of receptor ligands, resulting in
an increase in bleeding, which, in some conditions, may be more deleterious to the patient
than the clot itself. Michael Holinstat (Thomas
Jefferson University, PA, USA) advocated a
preferred therapeutic approach to treatment of
platelet clot formation: to target signaling components downstream of receptor activation.
Identification of these targets is a crucial first
step in the development of novel therapeutics
for the treatment of platelet clot formation with
a minimal effect on bleeding. For example, as
thrombin is the most potent activator in platelets, identification of targets downstream of its
receptors, PAR1 and PAR4, which result in
www.future-science.com
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attenuation, but not complete, inhibition of
platelet activation, would prove to be beneficial
to maintaining normal hemostasis.
Ion

channels as therapeutic targets
Ion channels are implicated in multiple diseases
of excitable and nonexcitable tissues. The single
biggest hurdle in exploiting ion channel targets
for drug discovery has been the limitation of
electrophysiology, the ‘gold standard’ tool for
ion channel activity, with regards to its throughput capacity. Joe McGivern (Amgen, CA, USA)
has overcome this insurmountable limitation by
developing automated platforms for a number
of voltage-gated ion channels, and used them
in primary screening and in selectivity profiling. Lori Jin (Cerep, Paris, France) extended
this concept in his poster presentation on the
screening of NaV1.5 blockers using automated
and conventional patch-clamp systems.
Temperature control during automated
patch clamp assays is critical in studying temperature-sensitive ion channel targets. Cecilia
Farre (Nanion, Munich, Germany) has developed a method for achieving rapid temperature
changes around patch-clamped cells and has
shown the method to be quite useful in characterizing heat inactivation of channels such
as TRPV1. According to Narender Gavva
(Amgen, CA, USA), members of the transient
receptor potential (TRP) ion channel superfamily are proposed to mediate various sensory functions such as touch, pain, taste and
thermosensation. TRP vanilloid (TRPV1–4),
melastatin (TRPM8) family members and
TRP ankyrin 1 (TRPA1) are directly activated
by either heat or cold and by compounds that
modulate sensations of warmth, cooling and
burning pain. Agonists of TRPA1, TRPM8
and TRPV1 either cause pain and neurogenic
inflammation or sensations of cold and pain in
humans, suggesting that antagonists of these
channels may be useful as analgesics. It appears
that on-target undesirable effects are major hurdles for TRPV1 antagonists to become therapeutics. Preclinical data indicate that TRPA1
and TRPM8 may potentially be more attractive
targets for analgesic discovery.
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Heike Wulff (University of California, CA,
USA) showed that calcium-activated potassium
channel KCa3.1 plays an important role in the
proliferation of dedifferentiated vascular discussed muscle cells, fibroblasts and lymphocytes.
The KCa3.1 blockers were shown as potential
new drugs to prevent restenosis, atherosclerosis
and renal fibrosis. Jerod Denton (Vanderbilt
University, TE, USA) discussed his group’s recent
discovery and characterization of small-molecule
inhibitors of the renal outer medullary potassium
channel and G-protein-coupled inwardly rectifying potassium channels. This fills the void with
regards to the virtual absence of critical information on the molecular pharmacology of the
inwardly rectifying K+ channel family.
The poster presentations were all of high
quality and relevance to the target discovery
theme of the conference. The poster presentations dealt with new technology platforms
(e.g., phage display, HCS and automated patch
clamp systems), new therapeutic targets (GC
binding factor 2 and transcription factors) and
novel probes (triarylamines as connexin blockers). Stephanie Leavitt (Gilead, CA, USA) gave
a well-received presentation on a fragment-based
drug-discovery approach using the Corning
Epic® system. In conjunction with the conference, two training courses, one dealing with
fluorescence assays and the other on enzyme and
binding assays in drug discovery, were presented
by Jack Owicki.
The conference organizers are to be commended for addressing a timely topic, and bringing together the experts in the field to share their
views on the current status of target discovery in
finding new, novel and safer drugs.
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